What You Should Know:
- A new study suggests that a weekly treatment with semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, may significantly reduce the risk of kidney failure and other complications in patients with type 2 diabetes and chronic kidney disease (CKD).Find semaglutide online today.
- Funded by Novo Nordisk creators of Ozempic and Wegovy semaglutide injections for diabetes management, the study published in The New England Journal of Medicine investigated
Read More
GLP-1
Dandelion Health Launches First Multimodal GLP-1 Data Library for Precision Medicine
What You Should Know:
- Dandelion Health, a leader in real-world data (RWD) and clinical AI, has unveiled the industry's first-ever multimodal GLP-1 data library.
- The multimodal GLP-1 data library empowers researchers and life sciences companies to unlock deeper insights into the use of glucagon-like peptide-1 (GLP-1) receptor agonist drugs for precision medicine.
Unprecedented Depth of Real-World Data
Gathered from Dandelion's network of collaborating medical centers,
Read More
LifeMD Integrates with Withings: GLP-1 Weight Loss with In-Home Monitoring
What You Should Know:
- LifeMD, Inc.® (Nasdaq: LFMD), a leading provider of virtual primary care services, and Withings Health Solutions, a leader in digital health technology, announce a new strategic partnership designed to revolutionize weight management patient care by providing LifeMD's GLP-1 weight-loss patients with Withings advanced in-home health monitoring devices, including the Body Pro 2 scale and
Read More
Lexaria Conducts Second Human Trial for Improved Oral GLP-1 Delivery
What You Should Know:
- Lexaria Bioscience Corp. is pushing the boundaries of oral drug delivery with their latest clinical trial.
- The company announced they have contracted a research organization (CRO) to conduct a second human pilot study on their DehydraTECH-powered glucagon-like peptide-1 (GLP-1) treatment.
GLP-1 Challenges and Lexaria's Solution
GLP-1 drugs, like semaglutide, are currently delivered through injections or tablets. However, these methods have limitations.
Read More
Teladoc Health Expands Obesity & Weight Management Capabilities with GLP-1 Support
What You Should Know:
Teladoc Health, Inc. (NYSE: TDOC), the global leader in whole-person virtual care, today announced expanded capabilities designed to help employers and health plans manage rising demand for anti-obesity medication such as glucagon-like peptide 1 (GLP-1) agonists and support safe, sustainable weight loss and cardiometabolic health improvement for members.New features include helping plan sponsors and pharmacy benefit managers manage and optimize the growing complexity and
Read More
WeightWatchers Launches First-Of-Its-Kind GLP-1 Program + WeightWatchers Clinic
What You Should Know:
- WeightWatchers launches two new offerings to further support individuals on their journeys to better health: the WeightWatchers GLP-1 Program and WeightWatchers Clinic integration within the WeightWatchers App.
- By focusing on personalization, scientific evidence, and comprehensive support, WW empowers individuals to take control of their weight health and achieve lasting results.
WeightWatchers GLP-1 Program
This program addresses the unique needs of
Read More
